1 The ability of captopril, 150 mg three times daily by mouth, to effect sustained reduction in
plasma angiotensin II, with converse increases in circulating angiotensin I, and in active …

1 The disposition of two angiotensin converting‐enzyme inhibitor drugs was studied in
normal volunteers. One drug was enalapril maleate (MK‐421), which requires in vivo …

Captopril, an angiotensin‐converting enzyme inhibitor with antihypertensive properties, was
given by mouth and intravenously in 10‐mg doses to five healthy subjects. After intravenous …

We show that for drugs metabolized by one enzyme the slope of a plot of serum
concentration (C) versus 1/clearance (CL) is linear with a value of 1/Vmax in the presence of …

The clearance of drugs excreted entirely unchanged by the kidneys is assumed to relate
directly to renal function. The clearance of drugs which are entirely metabolized is usually …

Captopril (SQ 14225) is a competitive inhibitor of converting enzyme. We are currently
comparing the efficacy of Captopril with propranolol in patients with mild to moderate WHO …

In view of recent indications that drug biotransformation processes may be inhibited in vivo
by the products of such processes, pharmacokinetic studies have been carried out to …

Throughout the literature, enzyme constants have been derived by utilizing in vivo data and
indirectly assuming that these data were described by the one-compartment open model …

The plasma concentration and urinary excretion of a newly developed angiotensin I
converting enzyme inhibitor, alacepril (which is converted to captopril after absorption), were …

When three intravenous doses of lisinopril were administered to healthy volunteers, area
under the curve (to infinity) vs dose was linear with a positive intercept. Subtracting area …